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Background: Previous studies from North America and Iceland have shown that the youngest children within a grade
are up to twice as likely to be diagnosed and treated for attention-deﬁcit/hyperactivity disorder (ADHD) compared
with their older classmates. We aimed to investigate whether younger age in class is associated with an increased
probability of being prescribed medication for ADHD among school-aged children in Denmark. Methods: We followed
all Danish children between 2000 and 2012 from 1st through 6th grade (7–12 years). Among children who started
school on their age-assigned grade level, we estimated the prevalence proportion ratio (PPR) of receiving ADHD
medication between the youngest children in class (born in October–December) and the oldest in class (born in
January–March), speciﬁed by grade level, calendar year and gender. As a sensitivity analysis, we added children not
on their age-assigned grade level to the main calculations. Results: We identiﬁed 932,032 eligible children for the
main analysis, of whom 17.3% were among the youngest and 26.5% among the oldest in class. In total, 1.2% eligible
children ﬁlled at least one prescription for ADHD medication in 2000–2012. The average PPR over the study period
was 1.08 (95% CI, 1.04–1.12) and remained stable across subgroups and sensitivity analyses. Overall, 40% of
children born October–December had entered school a year after their age-assigned grade level. Conclusions:
Contrary to previous study results, we observed almost no relative age effect on medication use for ADHD among
children in Denmark. We postulate that this may be due to the high proportion of relatively young children held back
by 1 year in the Danish school system and/or a generally low prevalence of ADHD medication use in the country.
Keywords: Attention-deﬁcit hyperactivity disorder, central stimulants, children, age factors, drug utilization
evaluation.
Introduction
Attention-deﬁcit/hyperactivity disorder (ADHD) is
one of the most commonly diagnosed mental condi-
tions in children and may have lasting effects
through adolescence and into adulthood (Biederman,
2005; Faraone, Biederman, & Mick, 2006; Steinhau-
sen, 2009). Itsdiagnosisin childrenis a multiple-step
process based on clinical evaluation, teacher ratings
of behavior and performance in school and parental
rating (Barkley & Edwards, 2006). The Diagnostic
and Statistical Manual of Mental Disorders standard
requires several symptoms to be present in two or
more settings (e.g. at school and home) with evidence
of clinically signiﬁcant impairment in social or
school/work functioning (American Psychiatric
Association, 2013). Over the past two decades, an
increasing number of children worldwide has been
diagnosed with the condition and use of medication
as a therapeutic option has risen (Asheim, Nilsen,
Johansen, & Furu, 2007; Castle, Aubert, Verbrugge,
Khalid, & Epstein, 2007; McCarthy et al., 2009;
Pottegard, Bjerregaard, Glintborg, Hallas, & Moreno,
2012; Pottegard et al., 2013; Schefﬂer, Hinshaw,
Modrek, & Levine, 2007; Winterstein et al., 2008;
Zoega, Baldursson, & Halldorsson, 2007; Zuvekas,
Vitiello, & Norquist, 2006). The underlying reasons
for this increase remain somewhat unclear.
Recent studies suggest that a within-grade relative
maturitydisadvantage in childhoodcould have long--
lastingnegativeeffectsonpersonalachievementsand
health outcomes (Bedard & Dhuey, 2006; Goodman,
Gledhill, & Ford, 2003; Helsen, Van Winckel, &
Williams, 2005). Studies from North America and
Iceland also showed that the youngest children in the
grade are more likely to be diagnosed and treated for
ADHD (Elder, 2010; Evans, Morrill, & Parente, 2010;
Morrow et al., 2012; Zo€ ega, Valdimarsd  ottir, &
Hern  andez-D  ıaz, 2012). The prevalence of use of
medication for ADHD in children ranged from 3.7%
to 6.3% in these studies, and the relative difference of
usebetweentheyoungestandtheoldestgroupsinthe
class ranged from approximately 50% (Canada, Ice-
land) to 100% (United States).
To better understand the structural and social
mechanisms at play, the association between relative
age in class and prescribing of medication for ADHD
needs further study. Understanding these associa-
tions may have an impact on how maturity differ-
ences in the classroom are evaluated and handled.
Importantly, they could have an impact on clinical
practice by avoiding unnecessary ADHD medication
of children relatively young or immature in class.
We hypothesize that being young relative to one’s
classmates increases the probability of being
Conﬂict of interest statement: See acknowledgements for
disclosures.
© 2014 The Authors. Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for Child and
Adolescent Mental Health.
ThisisanopenaccessarticleunderthetermsoftheCreativeCommonsAttribution-NonCommercial-NoDerivsLicense,whichpermitsuseanddistribution
in any medium, provided the original work is properly cited, the use is non-commercial and nomodiﬁcations or adaptations aremade.
Journal of Child Psychology and Psychiatry 55:11 (2014), pp 1244–1250 doi:10.1111/jcpp.12243prescribed medication for ADHD and that this prob-
ability varies by children’s grade level in school.
Further, we hypothesize that this phenomenon has
increased over the past decade with rising use of
ADHD medication in Denmark. These hypotheses
were addressed by using nationwide data on pre-
scribed psychotropic medication to children living in
Denmark 2000–2012.
Methods
For all children aged 7–12 years in Denmark, we obtained data
from nationwide registries during the period July 1, 2000–
June 31, 2012. To address the hypothesis that children’s
relative age in class inﬂuences their probability of receiving
medication for ADHD, we compared the 1-year period preva-
lence proportion of ADHD medication use between the oldest
and youngest children within a given grade level, thus using a
prevalence proportion ratio (PPR).
Data sources
The Danish National Prescription Registry (Kildemoes, Søren-
sen, & Hallas, 2011) contains data on all ﬁlled prescriptions
among Danish citizens since 1995. Prescription data include
the type of medication, quantity and date of dispensing, but
information on dosing and indication is not available. Drugs
are categorized according to the World Health Organization
(WHO) Anatomic Therapeutic Chemical (ATC) classiﬁcation
(WHO Collaborating Centre for Drug Statistics Methodology,
2012).
The Danish Student Register (Jensen & Rasmussen, 2011),
was used to obtain information of children’s school grade level.
Since 1973, the Student Register contains information on all
students in Denmark, attending 8th grade through PhD-train-
ing and, since 2007, data on the entire elementary school stage
have been added, from grade 0 onwards. For children who
entered school before 2007, we used children’s age in 8th grade
to assess whether or not they were on grade level.
The Danish Civil Registration System (Pedersen, 2011)
contains data on vital status (dates of birth and death) and
migrations to and from Denmark, which allowed us to keep
track of all study subjects.
We merged the different national registries by use of the
personal identiﬁcation number, a unique identiﬁer encoding
gender and date of birth, assigned to all Danish residents
(Pedersen,2011).DatalinkageswereperformedwithinStatistics
Denmark, a governmental institution that collects and main-
tains electronic records for statistical and scientiﬁc purposes.
Study population and relative age
By default, children start 1st grade in the calendar year of their
7-year birthday. Relative age in the Danish classroom, thus,
normally coincides with the order of birth months, i.e. children
born in January are the oldest and children born in December
are the youngest. However, parents may opt for a delayed entry
into grade school if their child is considered immature for his/
her age. Occasionally, they may opt for an early school entry if
their child is considered particularly mature.
We started observing the study children in the year they
attended 1st grade (age 7) and classiﬁed them into relative age
groups within the grade level depending on month of birth;
the oldest being born in January–March and the youngest
being born in October–December. Of 1,209,901 children aged
7–12 years identiﬁed during the study period, we excluded a
total of 75,378 (6.2%) children who did for one reason or
another did not appear in the Student Registry, i.e. those home
schooled, deceased, or with a delayed school entry during the
last study year.
Of the 1,209,901 identiﬁed children, 202,491 (16.7%) were
either behind (n = 173,791) or ahead (n = 30,543) of their
age-assigned grade level. Based on data from the Student
Register for study years 2008–2012, the vast majority (over
99%) of these children had entered school later or earlier than
their peers, but only 1% had repeated or skipped a grade. To
avoid the effect of misclassiﬁcation due to grade retention or
acceleration, we excluded all children (n = 202,491) not on
age-assigned grade level from the main analysis. Table 1
shows, however, that children behind their age-assigned grade
level were mainly the relatively youngest children, i.e. those
born in October–December, and were more likely to be boys
than girls, thus potentially introducing a selection bias. We
attempted to address the effects of such bias with multiple
sensitivity analyses as described below.
The main study population comprised 932,032 children on
age-assigned grade level in 1st through 6th grade (ages 7–12).
To examine whether the hypothesized relative age effect
continued through puberty, we then also analyzed data on
children on age-assigned grade level in 7th through 9th grade
(ages 13–15).
ADHD medication
We deﬁned medication for ADHD according to the ATC
classiﬁcation as the following substances within the category
of centrally acting sympathomimetics (N06BA): methylpheni-
date (N06BA04), atomoxetine (N06BA09) and modaﬁnil
(N06BA07). Children were considered prevalent users if they,
at any time during the relevant study year, ﬁlled a prescription
for any of these substances.
We deﬁned use of other psychotropic medication as the
ﬁlling of prescriptions for antiepileptics (N03), antipsychotics
(N05A), anxiolytics (N05B), hypnotics and sedatives (N05C), or
antidepressants (N06A) during the relevant study year.
Data analysis
The primary study outcome was the PPR of ADHD medication
use in 2000–2012, which we calculated by dividing the 1-year
prevalence proportion of ADHD medication use among the
youngest children in class (born in October–December) by the
1-year prevalence proportion among the oldest in class (born in
January–March). PPRs were ﬁrst calculated for each individual
stratum of study year (July 1–June 30), children’s grade level,
and gender and then reported as the average PPR from these
individual strata.
As sensitivity analyses, we conducted the same calculations
asinourmainanalysis,butchangedtheclassiﬁcationofrelative
age; comparing cohorts born in January with those born in
December,cohortsborninJanuary–Februarywiththosebornin
November–December, and ﬁnally children born in January–
AprilwiththoseborninSeptember–December.Furthermore,we
analyzed the PPR estimates by calendar period (2000–2005,
2006–2012),eachstudyyear,children’sgradelevel,gender,and
region of residence (the ﬁve Danish regions), as well as upon
exclusion of all children using other psychotropic medication.
Lastly, we ran sensitivity analyses to examine if our results
were affected by a selection bias due to exclusion of children
not on age-assigned grade level: we repeated the risk analysis
adding the excluded children who were behind or ahead of
their grade level separately to the main study population.
All calculations were performed using STATA Release 12.0
(StataCorp, College Station, TX). The Danish Data Protection
Agency and Statistics Denmark’s Scientiﬁc Board approved
this study. According to Danish law, ethical approval is not
required for registry-based studies.
© 2014 The Authors. Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for
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Of 932,032 children in the main analysis, 161,116
(17.3%) were born in October–December (relatively
young) and 246,596 (26.5%) in January–March
(relatively old). Among these, 10,932 (1.2%) children
ﬁlled at least one prescription for ADHD medication
while under observation: 10,786 (98.7%) for meth-
ylphenidate, 2,458 (22.5%) for atomoxetine and 69
(0.6%) for modaﬁnil. The 1-year prevalence propor-
tion of ADHD medication use in 2011–2012 speciﬁed
by birth month is depicted in Figure 1.
Over the study period (2000–2012), the 1-year
prevalence proportion of ADHD medication use
increased from 0.16 to 1.52 per 1,000 children
among the youngest children in class and from
0.13 to 0.91 per 1,000 children among those oldest
in class. The average PPR, comparing the relatively
youngest children with those relatively oldest was
1.08 (95% CI, 1.04–1.12) over the entire the study
period (2000–2012), but 0.93 (95% CI, 0.89–0.97)
during study years 2006–2012.
The relative age effect was similar between gen-
ders. The PPR was 1.11 (CI, 1.02–1.21) for boys and
1.05 (CI, 1.00–1.09) for girls averaged over all study
years and diminished respectively decreased to 0.89
(CI, 0.82–0.97) and 0.98 (CI, 0.93–1.02) in 2006–
2012.
Figure 2 shows that that the relative age effect was
only apparent children in 4th–8th grade (ages 10–14)
averaged over all study years. Throughout all study
years, the youngest children in 6th grade were
1.3-fold (95% CI, 1.19–1.41) more likely to use
ADHD medication compared with the oldest in 6th
Table 1 Number of children in Denmark in 1st grade to 6th grade on age-assigned grade level, behind (delayed) or ahead
(accelerated) of their grade level in school, according to birth month
Youngest in class (October–December) Oldest in class (January–March)
On grade level (%) Accelerated (%)
a Delayed (%)
a On grade level (%) Accelerated (%)
a Delayed (%)
a
Overall 112,095 (59) 1,758 (1) 76,750 (40) 176,728 (88) 14,619 (7) 8,572 (4)
Gender
Boys 45,814 (47) 1,098 (1) 49,812 (51) 91,806 (90) 4,686 (5) 5,750 (6)
Girls 66,281 (71) 660 (1) 26,938 (29) 84,922 (87) 9,933 (10) 2,822 (3)
Study year
2000 9,215 (57) 302 (2) 6,529 (41) 14,349 (85) 1,595 (9) 975 (6)
2001 10,077 (56) 358 (2) 7,510 (42) 14,802 (86) 1,507 (9) 889 (5)
2002 9,303 (55) 116 (1) 7,554 (45) 15,775 (87) 1,405 (8) 877 (5)
2003 9,181 (54) 117 (1) 7,848 (46) 15,209 (87) 1,232 (7) 954 (5)
2004 8,458 (53) 142 (1) 7,333 (46) 15,146 (88) 1,171 (7) 904 (5)
2005 8,591 (53) 112 (1) 7,444 (46) 14,708 (89) 1,045 (6) 851 (5)
2006 8,456 (53) 92 (1) 7,284 (46) 14,727 (89) 1,036 (6) 783 (5)
2007 9,324 (57) 106 (1) 7,065 (43) 14,904 (89) 1,111 (7) 674 (4)
2008 9,185 (58) 154 (1) 6,379 (41) 14,668 (89) 1,174 (7) 582 (4)
2009 9,187 (59) 88 (1) 6,233 (40) 14,256 (90) 1,118 (7) 542 (3)
2010 10,007 (64) 94 (1) 5,571 (36) 13,811 (89) 1,147 (7) 541 (3)
2011
b 11,111 (99) 77 (1)
b 14,373 (93) 1,078 (7)
b
aExcluded from the main study analysis. Included in sensitivity analyses for bias.
bChildren with delayed school entry in 1st grade 2011 were not registered in the Student Registry by the end of the study period and
did therefore not appear in any of the analyses.
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Figure 1 Prevalence proportions of ADHD medication use in
2011–2012 among children on age-assigned grade level, accord-
ing to birth month
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Figure 2 Prevalence proportion ratios* of ADHD medication use
with 95% conﬁdence intervals (dashed lines), comparing the
youngest (born October–December) with the oldest (born Janu-
ary–March) children in class, according to grade level in school.
*Prevalence proportion ratios are averaged over the total study
period and calculated only for children on age-assigned grade
level
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younger 6th grade students were no more likely than
the older 6th graders to use medication for ADHD,
PPR = 0.97 (95% CI, 0.88–1.06).
Figure 3 shows how the relative age effect for
children in 1st–6th grade diminished with time. In
the early study years, the relatively younger children
were up to 1.52-fold (95% CI, 1.17–1.95) more likely
than their older classmates to use medication for
ADHD, while the association disappeared in study
years 2004–2009 and became reversed in 2010–
2012. In 2011–2012 the youngest children in class
were 17% (PPR = 0.83, 95% CI, 0.75–0.92) less
likely to use ADHD medication than the oldest
children.
The results were not altered when we excluded
users of other psychotropic medication from the
analyses. Nor did stratiﬁcation by children’s region
of residence change the results (data not shown).
Altering the limits for classiﬁcation of relative age
groups had only a minimal effect on in the observed
relative age effect. Averaged over all study years, the
overall PPR was 1.11 (95% CI, 1.03–1.19) comparing
children born in December versus January; 1.02
(95% CI, 0.97–1.07) comparing children born in
January–February versus November–December; and
ﬁnally 1.14 (95% CI, 1.10–1.17) comparing those
born in January–April versus September–December.
Finally, our sensitivity analyses for potential selec-
tion bias due to a higher proportion of excluded
children born in October–December than January–
March indicated that the study results were not
affected by this exclusion. Adding children behind
their age-assigned grade level to the main risk
calculations changed the overall PPR from 1.08 to
1.09 (95% CI, 1.06–1.12).
Discussion
Contrary to our hypothesis, we found nearly no
overall association between relative age among
classmates and use of medication for ADHD for
children in Denmark. The results of this nationwide
study suggested a slightly increased probability of
ADHD medication use for the relatively youngest
children in grades 4th–8th during study years 2000–
2004 only. But opposite to the expected, while the
use of medication for ADHD became more frequent
in Denmark, the slight relative age effect on ADHD
medication use decreased and then vanished alto-
gether in 2005–2012.
The strength of this study lies in its nationwide
approach, covering nearly 1 million children in
Denmark over more than a decade. Furthermore,
the individual-level linkage with the Student Regis-
try allowed for a detailed assessment of the use of
medication for ADHD among children not attending
their age-assigned grade level. The validity of the
Danish prescription data used is regarded to be very
high (Kildemoes et al., 2011). Denmark has a pub-
licly funded educational system and universal
health care, which may limit the generalizability of
our results to other populations. However, we ﬁnd
the Danish classroom to be a key advantage to this
study, as the high number of relatively young
children with a delayed school entry allows for
interpretations beyond those of previous studies on
the subject in question. Given the nature of the
exposure of interest (i.e. birth month), this observa-
tional study design is in effect a quasi-randomized
natural experiment, with comparable risk factors
distribution among relative age groups within a
grade, except for season of birth. However, to avoid
misclassiﬁcation of relative age groups, we excluded
children not on age-assigned grade level. This
exclusion might in turn have distorted an otherwise
equal risk factor distribution. The excluded children
were more likely to be born in October–December,
than during other months, and also more likely to be
boys than girls. Nevertheless, our sensitivity analy-
ses indicated that the study results remained almost
the same irrespective of whether children behind or
accelerated in school were included to the risk
calculations.
Among the major limitations of the study are the
abovementioned characteristics of the study setting,
i.e. the publicly funded universal health care and
education, structural and cultural factors, which
may, additional to acting as a key advantage, com-
promise the generalizability of the results. Secondly,
the study design is based on ﬁlled prescriptions for
ADHD medication but not diagnoses of ADHD.
Optimally, the study data would have captured all
children a diagnosed with ADHD irrespective of
treatment status. Finally, in this, we do not assess
whether the intensity or duration of treatment with
ADHD medication is associated with children’s
relative age in class, which could be interesting to
examine in future studies.
The near absence of a relative age effect on the use
of medication for ADHD in Denmark contrasts what
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Figure 3 Prevalence proportion ratios* with 95% conﬁdence
intervals (dashed lines), comparing the youngest (born Octo-
ber–December) with the oldest (born January–March) children in
class, according to study year (July 1- June 30). *Prevalence
proportion ratios are averaged over all grade levels (1st–6th) and
calculated only for children on age-assigned grade level
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land, Canada and the United States. Recent data on
12,000 children in Iceland in 2003–2008, indicated
that the youngest third of children in the elementary
school class were over 50% more likely to be
prescribed stimulants for ADHD compared with the
oldest third (Zo€ ega et al., 2012). The youngest chil-
dren in the Icelandic classroom were also at greater
risk for poor academic performance on standardized
tests in mathematics and language arts. Similarly,
Morrow et al. (2012) found in a recent study of
900,000 children in British Columbia, Canada, that
boys and girls born in December were 41% and 77%
more likely, than those born in January, to be
prescribed stimulants for ADHD. Finally, the inﬂu-
ence of relative age on ADHD treatment has been
demonstrated in two different datasets within the
United States. Based on longitudinal survey data
from almost 12,000 US children, Elder (2010)
showed that the youngest children in 5th and 8th
grades were nearly twice as likely as their older
classmates to use stimulants for ADHD. Similarly,
based on cross-sectional US survey data, Evans
et al. (2010) found that among children 7–17 years
the youngest third of children in class had, com-
pared with the oldest third, double the chance of
being diagnosed with or treated for ADHD.
None of the above studies have, however, con-
cluded about the potential effect of holding children
back in school on their ﬁndings. In our data, as
many as 51% of boys and 29% of girls born in
October–December were behind their age-assigned
grade level, the vast majority of whom had been
delayed at school entry rather than being held back
by a grade later in school. It is highly conceivable
that delaying school entry for relatively young and
immature children could be perceived as a preven-
tive measure to later being diagnosed and treated for
ADHD. Notably, Elder and Lubotsky (2009) used
comprehensive survey data to demonstrate, that
children in the United States, who were an additional
year older at school entry tended to have higher test
scores and fewer behavioral problems than those
starting school a year younger. Importantly, the
authors found that starting school later reduced
the chance of being diagnosed with ADHD by 50%.
We propose that the high proportion of relatively
young children with delayed school entry in Den-
mark may play a role in the near absence of a relative
age effect in our data. The conventional 12-month
age span of children at school entry presents con-
siderable differences in maturity and performance
between the youngest and the oldest child in class
(West, Denton, & Germino-Hausken, 2000). In addi-
tion to previous ﬁndings on the relative age effect on
ADHD and treatment thereof, recent evidence also
suggests that a relative maturity disadvantage in
childhood could have long-lasting negative effects
on personal achievements and health outcomes
(Bedard & Dhuey, 2006; Goodman et al., 2003;
Helsen et al., 2005). If delaying school entry for
immature children does indeed prevent ADHD diag-
noses and treatment, such knowledge could be of
major importance for the policy regarding school
entry and for the wellbeing of children. The potential
beneﬁts of delaying school entry for immature chil-
dren thus warrant further investigation.
The contrasting ﬁndings between the Danish and
previous results regarding the effect of relative age
on ADHD medication, might also be explained by low
prescribing rates of medication for ADHD to children
in Denmark. The national prevalence of use among
school-aged children is considerably lower in Den-
mark (0.9% in 7–15 year-olds, 2007) than in North
America (4.6% in 6–12 year-olds, 2007) and Iceland
(4.7% in 7–15 year-olds, 2007), where the relative
age effect has been reported (Zoega et al., 2011;
Zuvekas & Vitiello, 2012). Rates of ADHD medication
use are also lower than the estimated worldwide
prevalence of ADHD in children (Polanczyk, de Lima,
Horta, Biederman, & Rohde, 2007; Pottegard et al.,
2012), indicating that clinicians in Denmark may be
more restrictive when prescribing medication for
ADHD than elsewhere. It is possible that the effect
of relative age can be partly ascribed to use of ADHD
medication in children who are immature rather
than affected by ADHD, and that a restrictive policy
would channel the medication more toward children
who have ADHD in its core sense.
In conclusion, we found that in most recent years
the use of medication for ADHD in Denmark is not
particularly affected by children’s relative age in
class. This may be related to the relatively low use of
ADHD medication the country and the highly pre-
vailing custom of delaying school entry for relatively
young children.
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Key points
￿ Previous studies from North America and Iceland have shown that the youngest children within a grade are up
to twice as likely to be diagnosed and treated for ADHD compared with their older classmates.
￿ The use of medication for ADHD in Denmark is not particularly associated with children’s relative age in class.
This might be due to the highly prevailing custom in Denmark of delaying school entry for the youngest
children in school cohorts.
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